Price
No data yet.
Social Signal Score
Analyst Ratings
34 analystsRevenue
$3.04B+61.43%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James E. Davis
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 51,500
- Beta
- 0.55
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 3.63
Financials
Revenue
$3.04B+61.4%Net Income
$320.00M+68.4%EBITDA
$481.00M+23.7%Free Cash Flow
$330.00M+37.5%EPS (diluted)
$2.84+111.9%Shares Outstanding (diluted)
112.00M-21.1%Operating Expenses
$529.00MCash & Debt
$626.00MReturn of Capital
$198.00MRevenue by Segment (annual)
$10.79BDividend per Share
$0.86Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.04B | $992.00M | $8.87 |
| 2024 | $9.87B | $871.00M | $7.80 |
| 2023 | $9.25B | $854.00M | $7.59 |
| 2022 | $9.88B | $946.00M | $8.12 |
| 2021 | $10.79B | $2.00B | $15.90 |
| 2020 | $9.44B | $1.43B | $10.68 |
| 2019 | $7.73B | $858.00M | $6.38 |
| 2018 | $7.53B | $736.00M | $5.41 |
| 2017 | $7.71B | $772.00M | $5.63 |
| 2016 | $7.51B | $645.00M | $4.58 |
| 2015 | $7.49B | $709.00M | $4.92 |
| 2014 | $7.43B | $556.00M | $3.83 |
| 2013 | $7.15B | $849.00M | $5.58 |
| 2012 | $7.38B | $555.70M | $3.49 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DGX's reported EPS growth of 7.4% a year over 13 years.
- EPS in 5 years
- $12.77
- Implied price
- $255.41
- Return from $233.24
- 1.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $126.98 — -45.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.6% | -14.0% | -10.6% | -7.6% | -5.0% | -2.7% |
| 2.4% | -9.6% | -6.0% | -2.9% | -0.2% | 2.3% |
| 7.4% | -5.2% | -1.4% | 1.8% | 4.7% | 7.3% |
| 12.4% | -0.8% | 3.2% | 6.6% | 9.6% | 12.3% |
| 17.4% | 3.7% | 7.8% | 11.3% | 14.5% | 17.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30+0.00%Social Signal Score
Mentions (37)
- Newsprnewswire.com·5d ago·Negative
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual
View source ↗ - PodcastAll In·7d ago·Positive
we're going to be able to draw super interesting conclusions about that, not just echo, but the whole healthcare system. Yeah. That's really the bad we're making. Put it in the wearables in there. It's going to be really interesting with the aura as the roots, the fit bits. You start up a watch, you start correlating that data with the blood work. I noticed roof offering labs now through Quest and I don't think, maybe you can sink, you know, you are aura with some of those. But we don't, I haven
View source ↗ - News (RSS)financialpost·10d ago·Neutral
Quest PharmaTech Announces Change of Chief Executive Officer EDMONTON, Alberta, Sept. 25, 2026 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, today announces the change of its Chief Executive Officer (CEO). Effective November 23, 2026, Dr. Madi Madiyalakan will be […]
View source ↗ - Newszacks.com·11d ago·Positive
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
View source ↗ - News (RSS)seekingalpha·12d ago·Positive
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
View source ↗ - Newsseekingalpha.com·13d ago·Positive
…iagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
View source ↗ - Newsprnewswire.com·13d ago·Neutral
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026 SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.
View source ↗ - News (RSS)zerohedge·13d ago·Neutral
…ssion. Grab (GRAB) rises 6% after Chief Executive Officer Anthony Ping Yeow Tan disclosed a $29.9 million stock purchase in a filing with the SEC. Quest Diagnostics (DGX) falls 6% after the Centers for Medicare & Medicaid Services released new preliminary medicare payment rates for lab services. Vicor (VICR) jumps 9% after the power equipment company raised its third-quarter revenue growth guidance, citing royalties from non-exclusive license to Vertical Power Delivery. Viking Therapeutics (VKTX…
View source ↗ - Newszacks.com·13d ago·Positive
Quest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.
View source ↗ - Newszacks.com·14d ago·Positive
Is This the Right Time to Add DGX Stock to Your Portfolio? Quest Diagnostics gains momentum from customer wins, advanced diagnostics and AI initiatives, while reimbursement uncertainty, costs and debt pose challenges.
View source ↗ - News (RSS)investing·14d ago·Neutral
Why is Quest Diagnostics stock sliding today?
View source ↗ - Newsmarketbeat.com·15d ago·Positive
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges Quest Diagnostics NYSE: DGX CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions.
View source ↗ - Newsprnewswire.com·15d ago·Positive
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies against other tick-borne pathogens compared to those without. SECAUCUS, N.J.
View source ↗ - Newsprnewswire.com·20d ago·Negative
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics 75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are scheduled to take effect January 2027 SECAUCUS, N.J., Sept. 16, 2026 /PRNewswire/ -- A new national survey finds the overwhelming majority of Amer…
View source ↗ - News (RSS)investing·20d ago·Neutral
Quest Diagnostics stock hits all-time high at $247.3
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript Quest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·21d ago·Positive
Quest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)bbc·25d ago·Positive
'We never recovered him': Quest to identify remains from Ground Zero continues Since the attacks, New York officials are working with new, complex technology to find traces of more than 1,000 victims.
View source ↗ - News (RSS)investing·26d ago·Neutral
Quest to offer lab testing through Apple Health app for $119
View source ↗ - News (RSS)fool·27d ago·Negative
Quest Diagnostics CEO Sells 10,000 Shares for $2.4 Million J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.
View source ↗ - 4chan /biz/biz·31d ago·Neutral
>>62659986 What's the ticker for DGX?
View source ↗ - 4chan /biz/biz·31d ago·Neutral
>DGX Spark went up 28% over night >Nvidia only up 1% How is this legal?
View source ↗ - News (RSS)venturebeat·34d ago·Neutral
…tic platform, arrived in March 2026, followed by desktop apps for Mac and Windows. Just last week, the company launched a local-first version of Computer on NVIDIA's DGX Spark hardware, which starts on the user's device and escalates to cloud models only with permission. Today's launch inverts that flow: cloud-first, delegating down.The business trajectory has been equally steep. Perplexity was valued at $520 million in January 2024; by September 2025, the company had finalized a funding round a…
View source ↗ - Newszacks.com·35d ago·Positive
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - News (RSS)zerohedge·39d ago·Negative
…r millions of families navigating the uncertainty of Alzheimer's disease, a timely diagnosis is the first and most critical step toward meaningful care." Labcorp and Quest Diagnostics said they will carry the new test. Once ordered by a doctor, patients can have their blood drawn for the test in a doctor's office, a Labcorp service center, or a Quest center. Tyler Durden Thu, 08/27/2026 - 23:00
View source ↗ - Newsprnewswire.com·40d ago·Neutral
Quest Global renforce son partenariat stratégique avec Babcock grâce à un accord-cadre quinquennal portant sur des services d'ingénierie groupés /PRNewswire/ -- Quest Global Engineering Services Limited, l'une des plus grandes sociétés indépendantes spécialisées exclusivement dans les services
View source ↗ - News (RSS)nyt·41d ago·Negative
Bessent Faces Credibility Test in Quest to Tame Markets The Treasury secretary is confronting the limits of his ability to reshape the economy ahead of midterm elections.
View source ↗ - News (RSS)venturebeat·41d ago·Neutral
…rplexity is launching Portable Computer today, a version of its agentic "Computer" platform that runs entirely on hardware users already own — starting with Nvidia's DGX Spark desktop supercomputer and Linux machines equipped with Nvidia RTX GPUs.The launch, developed in close partnership with Nvidia, is one of the most aggressive attempts yet to move serious AI agent workloads off the cloud and onto local devices. The model, the user's files, and the work itself can all stay on the machine. Wor…
View source ↗ - Newsprnewswire.com·42d ago·Positive
…sumer-initiated testing platform LONDON, Aug. 25, 2026 /PRNewswire/ -- Humanity Health Inc. ("Humanity"), the longevity science company, and Quest Diagnostics (NYSE: DGX) today announced that Humanity Biological Age, Humanity's scientifically validated model for measuring biological age from biomarker lab test results, is now available in the United States for the first time through questhealth.com, Quest's consumer-initiated testing platform. Individuals now have the option to select the Humani…
View source ↗ - News (RSS)zerohedge·44d ago·Neutral
A Call To Power: Islamic Leaders See Ballot Box As Path To Paradise A Call To Power: Islamic Leaders See Ballot Box As Path To Paradise Authored by Paul Sperry via RealClearInvestigations, The call to prayer is sounding across America. From Hamtramck, Michigan, to Paterson, New Jersey, to Minneapolis, Minnesota, rooftop amplifiers remind growing numbers of Muslim faithful five times a day of their duties with the Arabic message that "Allah is the Greatest! There is no god but Allah!" The so-call
View source ↗ - Newszacks.com·45d ago·Neutral
Is it the Right Time to Retain DGX Stock in Your Portfolio? Quest Diagnostics' growth across key channels and advanced diagnostics supports its outlook, but debt and reimbursement risks remain.
View source ↗ - Newszacks.com·45d ago·Positive
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newszacks.com·48d ago·Positive
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - News (RSS)venturebeat·49d ago·Positive
…al becomes clearer when the model is compressed. Developer and AI writer Simon Willison tested a roughly 17GB Q4_K_M quantization on an M5 Max MacBook Pro and Nvidia DGX Spark. He found that it could write code, interpret images and operate a coding-agent loop through the Pi agent framework. In one experiment, the model navigated a codebase to explain how authentication worked; in another, it wrote and tested a Python utility Willison needed to convert an agent transcript from JSONL to Markdown.…
View source ↗ - Newszacks.com·49d ago·Positive
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·52d ago·Neutral
Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsprnewswire.com·54d ago·Negative
Quest Diagnostics Declares Quarterly Cash Dividend SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.
View source ↗
Earnings
Thu, Oct 22(in 2 weeks)
Consensus estimate $2.87 per share
Typical surprise +2.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$3.12 vs $2.82beat
- Tue, Apr 21$2.50 vs $2.37beat
- Tue, Feb 10$2.42 vs $2.36beat
- Tue, Oct 21$2.60 vs $2.50beat
- Tue, Jul 22$2.62 vs $2.57beat
- Tue, Apr 22$2.21 vs $2.15beat
Estimates and results for DGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DGX officers and directors.
- Bought
- —
- Sold
- $18.1m
0 trades
18 trades
- Davis J. E.sold
- Prevoznik Michael Esold
- Prevoznik Michael Esold
- Prevoznik Michael Esold
- Delaney Mark Esold
- Kuppusamy Karthiksold
- Davis J. E.sold
- Doherty Catherine T.sold
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Carol Devine Millerhouse · WV01 · disclosed Aug 14, 2026 (522d later)Sell$15,001 - $50,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (280d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (280d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (173d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (260d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Dec 12, 2025 (39d later)Sell$1,001 - $15,000
- Carol Devine Millerhouse · WV01 · disclosed Apr 11, 2025 (32d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Feb 12, 2025 (19d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
- Earl Blumenauerhouse · OR03 · disclosed May 4, 2024 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Feb 14, 2024 (42d later)Sell$15,001 - $50,000
- Thomas Richard Carpersenate · DE · disclosed Jan 3, 2024 (23d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (8d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 6, 2023 (30d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Buy$1,001 - $15,000
- Carol Devine Millerhouse · WV03 · disclosed Dec 13, 2022 (29d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.